Evidence map›Paper›PMID 35493318›Full record

ReviewFrontiers in molecular neuroscience2022

Lipocalin-2 and Cerebral Stroke.

Chao Luo, Shuai Zhou, Shi Yin, Lipeng Jian, Pengren Luo, Jigeng Dong, Erheng Liu

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in molecular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chao LuoDepartment of Neurosurgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Shuai ZhouDepartment of Neurosurgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Shi YinDepartment of Neurosurgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Lipeng JianDepartment of Neurosurgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Pengren LuoDepartment of Neurosurgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Jigeng DongDepartment of Neurosurgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Erheng LiuDepartment of Neurosurgery, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, China.
Kunming University of Science and Technology · CNFirst People's Hospital of Yunnan Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stroke is a common and devastating disease with an escalating prevalence worldwide. The known secondary injuries after stroke include cell death, neuroinflammation, blood-brain barrier disruption, oxidative stress, iron dysregulation, and neurovascular unit dysfunction. Lipocalin-2 (LCN-2) is a neutrophil gelatinase-associated protein that influences diverse cellular processes during a stroke. The role of LCN-2 has been widely recognized in the peripheral system; however, recent findings have revealed that there are links between LCN-2 and secondary injury and diseases in the central nervous system. Novel roles of LCN-2 in neurons, microglia, astrocytes, and endothelial cells have also been demonstrated. Here, we review the evidence on the regulatory roles of LCN-2 in secondary injuries following a stroke from various perspectives and the pathological mechanisms involved in the modulation of stroke. Overall, our review suggests that LCN-2 is a promising target to promote a better understanding of the neuropathology of stroke.

Indexed as

blood brain barriercentral nervous systemcerebral strokeiron dysregulationlipocalin-2 (LCN-2)neurovascular unit (NVU)secondary injury

Identifiers

PMID35493318
PMCPMC9039332
OpenAlexW4223553094

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.